Health Catalyst (NASDAQ:HCAT) Given New $8.00 Price Target at Piper Sandler

Health Catalyst (NASDAQ:HCAT) had its target price decreased by Piper Sandler from $12.00 to $8.00 in a research note published on Tuesday morning,Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

HCAT has been the subject of a number of other reports. Stephens raised their price objective on Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a research report on Thursday, November 14th. Royal Bank of Canada dropped their target price on Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 15th. Canaccord Genuity Group dropped their target price on Health Catalyst from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, January 21st. Citigroup dropped their target price on Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a research report on Friday, January 10th. Finally, KeyCorp raised Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 target price for the company in a research report on Wednesday, January 8th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, Health Catalyst presently has an average rating of “Moderate Buy” and an average price target of $10.20.

Health Catalyst Stock Down 4.3 %

Shares of NASDAQ:HCAT opened at $5.50 on Tuesday. The business has a 50-day moving average price of $6.74 and a 200 day moving average price of $7.40. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $334.66 million, a price-to-earnings ratio of -4.07 and a beta of 1.34. Health Catalyst has a 12-month low of $5.32 and a 12-month high of $10.31.

Insider Transactions at Health Catalyst

In related news, COO Daniel Lesueur sold 5,209 shares of the business’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $5.76, for a total transaction of $30,003.84. Following the completion of the sale, the chief operating officer now owns 86,044 shares in the company, valued at $495,613.44. The trade was a 5.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Jason Alger sold 19,599 shares of the business’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $8.32, for a total value of $163,063.68. Following the sale, the chief financial officer now owns 86,712 shares of the company’s stock, valued at approximately $721,443.84. The trade was a 18.44 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 81,169 shares of company stock valued at $629,068. 2.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Health Catalyst

Several institutional investors have recently added to or reduced their stakes in the business. Impax Asset Management Group plc lifted its stake in Health Catalyst by 7.7% during the fourth quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company’s stock worth $19,442,000 after purchasing an additional 195,525 shares during the last quarter. Primecap Management Co. CA lifted its stake in Health Catalyst by 1.1% during the third quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company’s stock worth $19,572,000 after purchasing an additional 25,000 shares during the last quarter. Nepsis Inc. lifted its stake in Health Catalyst by 67.9% during the third quarter. Nepsis Inc. now owns 2,104,528 shares of the company’s stock worth $17,131,000 after purchasing an additional 851,448 shares during the last quarter. Geode Capital Management LLC lifted its stake in Health Catalyst by 4.9% during the third quarter. Geode Capital Management LLC now owns 1,443,036 shares of the company’s stock worth $11,749,000 after purchasing an additional 66,896 shares during the last quarter. Finally, State Street Corp lifted its stake in Health Catalyst by 2.5% in the third quarter. State Street Corp now owns 1,163,754 shares of the company’s stock valued at $9,473,000 after buying an additional 28,251 shares during the last quarter. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.